Audit: QRS - GABA for Health & Longevity
Audit conducted on 19/09/2026 03:30 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 93 |
| Passed | 85 |
| Failed | 0 |
| N/A | 8 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Every span traced to ER source: protocol cells to ER Therapeutic Protocol (lines 348, 350, 360), time cells to Practical Considerations (line 409) and Monitoring Protocol (line 439), benefit/risk tiers to ER sub-headings, gates to Key Interactions & Contraindications (lines 297-324), monitoring rows to the ER biomarker table (lines 441-450), qualitative items to ER lines 454-458. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | time_3_sub keeps the ER hedge “where they occur at all” as “Where changes occur at all”; action_3_sub keeps “morning dosing has not been studied”; marker_4_target keeps “No established target”. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | Pregnancy/lactation is carried as a contraindication, matching the ER’s “Populations who should avoid GABA” list (line 319), and separately as a Low risk “unclear safety during pregnancy and lactation” matching ER line 259. No tier or gate was up- or down-graded. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Contraindications come only from the ER’s “Populations who should avoid GABA” list; Key Interactions only from the ER interaction bullets; no Benefit- or Risk-Modifying Factor (ER lines 210-220, 284-292) appears anywhere in the QRS. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | No PMIDs, author names, NCT IDs or brand names in the QRS. The generic drug names in the gates (lisinopril, amlodipine, diazepam, zolpidem, gabapentin, pregabalin, valproate, vigabatrin, mirtazapine, diphenhydramine) all appear in the same ER bullets (lines 297-315). |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No attributions of any kind appear in the QRS body. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Measured, non-promotional register carried over, including the ER’s British orthography (“favourable”, “apnoea”, “haemoglobin”, “signalling”, “behavioural”). |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Numeric targets and thresholds throughout (lines 452, 465, 634, 662, 691) paired with plain-language “why” columns. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Statements are descriptive (“Taken 30 to 60 minutes before bed”, line 469) rather than instructional imperatives. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | No imperative or second-person instruction anywhere in the document body. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | No occurrence of “recommend”, “advise”, “should”, “must” or “consider” in the document voice. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person pronouns anywhere in the file. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Technical terms that remain are decision-bearing and required by sections 8 and 14 (e.g., “Child-Pugh Class C” line 566, “obstructive sleep apnoea” line 565); the At-A-Glance and “Why” columns are plain. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Tier lines are single semicolon-joined strings; gate items are noun phrases; monitoring “why” cells are single clauses. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed: no “you”, “your”, “we”, “our”, “us” in the file. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Functional ranges rather than conventional cut-offs are used throughout Monitoring (lines 634, 662, 691, 705), which is the proactive-optimizer frame. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Qualitative Assessment asks for nightly logging and a deliberate two-week washout (lines 760, 780). |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Eight-biomarker panel with a six-to-twelve-month cadence (lines 620-750) presumes a motivated, self-quantifying user. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | The longevity-specific caveat is retained as a Speculative risk, “possible opposition to longevity signalling” (line 611), which is precisely the audience-specific weighting from ER line 277. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | No occurrence of “anti-aging” or “antiaging”; “longevity” is used at lines 22, 417 and 611. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt. | 🟢 | The lede uses “oral supplement” and “oral dose” (lines 434-435), not lay route phrasing; no “pill”, “shot”, “taken by mouth” or “bad reaction” anywhere. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All present verbatim: Protocol (445), Time to effect (488), Benefits (536), Risk & Side Effects (595), Monitoring (619), Qualitative Assessment (756), Contraindications (560), Key Interactions (573), Marker/Target/Why (623-625), tier labels at 540, 544, 551, 599, 603, 610. |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | Diff against the template variable inventory shows every template variable present; the repeating marker_#_* and qualitative_item_# template rows are expanded to marker_1-marker_8 and qualitative_item_1-qualitative_item_5. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | A structural diff of the QRS against the template with all variable contents blanked shows differences only inside data-qrs-var spans, the metadata block and <title>; the header subline spans website="evidence_review", website="audit" and website="full_review" are untouched (lines 423, 426, 439). |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No section of the source ER is empty; the High benefit and High risk tiers carry explanatory prose (ER lines 153, 229) rather than empty-state phrasing, and are governed by items 12.5 / 13.5. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | “Standard relaxation dose” (449), “Sleep-onset dose” (462) and “Best time of day” (475) match the ER bold labels at lines 348, 350 and 360 exactly. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | Protocol labels are ER-verbatim; monitoring marker names match the ER biomarker column verbatim (lines 631, 644, 659, 672, 687, 702, 715, 730 vs ER 443-450). |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | No emoji characters in the file; the ER’s ⚠️ and ⭕️ markers were dropped when the tier items were condensed. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Each section is at its minimum permitted volume: tier lines are single semicolon-joined strings, gate items are bare noun phrases with trimmed drug lists, and the biomarker and interaction counts are the ones items 14.2 and 9.2 mandate in full. Nothing remains that could be condensed without violating another item. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Lines 2-14; the only content between <!doctype html> (line 1) and the template banner comment (line 16). |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Opening --- at line 3, closing --- at line 13; the preamble text sits on line 2. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Enclosed in an HTML comment; no metadata value is echoed into the body except qrs_creation_date and qrs_creator_ai_fullname, which items 6.3 and 6.4 require. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Only duration: "00:02" (line 10) is quoted, and it contains a colon, which requires it. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | Line 4: er_filename: gaba_2026-0919-0003_Opus_ER.md. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | Line 5: qrs_prompt_version: 26.9.11, matching the QRS.md version badge. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | Line 6: qrs_creation_date: 2026-0919-0257. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | Line 7: qrs_creator_ai_nickname: Opus. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” is a single word with no version or qualifier. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | Line 8: qrs_creator_ai_fullname: Opus 5. |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” is nickname plus version with no qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | Line 9: qrs_filename: gaba_2026-0919-0003_Opus_QRS.html, matching the file on disk. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Re-verified across all nine keys; no stray whitespace and no unnecessary quoting. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | Line 22: “GABA for Health & Longevity - Quick Reference Sheet”; ER canonical_topic is “GABA for Health & Longevity” (ER line 8). |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | Line 417: “GABA for Health & Longevity”. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | Line 421: “09/19/2026”, the correct reformat of 2026-0919-0257. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | Line 425: “Opus 5”, matching the frontmatter value. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | The header block (lines 415-428) contains only the title and the template subline; the ER’s “Also known as” line was not carried over. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Lines 434-437 compress all three Conclusion paragraphs (ER 478-482) into four sentences: identity and form, the unresolved brain-penetration question, the thin-but-not-negative benefit signal, and the safety verdict. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | 57 words. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Sentence 1 ← ER 478; sentence 2 ← ER 478; sentence 3 ← ER 480; sentence 4 ← ER 482. |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | Only “GABA” appears, which is the ER’s canonical_name and the subject of the sheet; everything else is plain (“calming signal”, “faster sleep onset”, “a modest fall in blood pressure”). |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No author name, year, n, or p-value; only the unattributed “Small studies”. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No numbers of any kind in the At-A-Glance text. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All six items map to the ER’s “Populations who should avoid GABA” list (ER lines 317-324). |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All six ER avoid-populations are present, none added: pregnancy/lactation, symptomatic hypotension, untreated OSA, severe liver impairment, prescription sedatives without supervision, children and adolescents. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Lines 563-568, six <li> elements inside the stop_items span. |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Every ER rationale clause was stripped (“on the grounds that no exposure data exist…”, “where added sedation may worsen breathing during sleep”, “the most severe grade of liver failure”); no dashes appear in any item. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Threshold “below 100 mmHg” (564), severity “moderate-to-severe” and “untreated” (565), staging “(Child-Pugh Class C)” (566) all retained. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER’s contraindication list uses no ranking notation inside parentheses. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | The ER does identify such populations and the section is correspondingly populated, not empty. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All ten items map one-to-one onto the ten ER interaction bullets (ER lines 297-315). |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | All ten ER interaction bullets are present in ER order; none duplicates a contraindication item, which name populations rather than the ER’s interaction categories. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Lines 576-585, ten <li> elements inside the caution_items span. |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | All ER mechanism and mitigation sentences dropped; each item is a category plus a parenthetical example list, with no dashes. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Every ER bullet that names examples keeps a trimmed parenthetical (lisinopril/amlodipine, diazepam/zolpidem, gabapentin/pregabalin, valproate/vigabatrin, mirtazapine, diphenhydramine, nitrate/magnesium, valerian/melatonin, cognitive behavioural therapy); “Alcohol” (581) is the only ER bullet with no examples to carry. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER interaction bullets use no ranking notation inside parentheses. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | The ER identifies ten such interactions and the section is correspondingly populated, not empty. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | All three cells come from the ER Therapeutic Protocol bullets at lines 348, 350 and 360. |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | The two studied dose regimens plus timing are selected; the growth-hormone dose (ER line 352) is correctly passed over as the ER states it “has no demonstrated functional payoff”. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER Therapeutic Protocol section provides fourteen bullets, well above three. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All nine spans populated (lines 449-483) and each traces to its ER bullet: 100 mg / pre-stressor (ER 348), 100 to 300 mg / pre-bed with the commercial-serving note (ER 350), Evening / morning untested (ER 360). |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Stress and mood, sleep onset and blood pressure are exactly the three the ER names in its “Time to effect” bullet (ER line 409). |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Order follows the ER benefit tiers: stress and mood is the only Medium benefit (ER 157), sleep onset is the first Low benefit (ER 165), blood pressure the second (ER 171). |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER provides three distinct time-to-effect aspects. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | All nine spans populated (lines 494-528); values “30 to 60 minutes” twice and “2 to 4 weeks” match ER line 409, and the sleep sub-note matches ER line 439. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER does provide time-to-effect information, so the section is retained. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | Every listed benefit is an ER Expected Benefits sub-heading (ER lines 157-205). |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four spans present at lines 538, 539, 542 and 549. |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each tier is a semicolon-joined list of bare ER headings; no Magnitude figure, trial or author from ER lines 159-205 was carried over. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses appear in any benefits item. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | 🟢 | Line 538: benefits_high carries style="display: none" with no inner <li>, matching ER line 153 (“No benefit reaches High”). |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | Every listed risk is an ER Potential Risks & Side Effects sub-heading (ER lines 233-279). |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four spans present at lines 597, 598, 601 and 608. |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each tier is a semicolon-joined list of bare ER headings; the incidence figures at ER lines 237 and 251 and the safety-review attributions were dropped. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses appear in any risks item. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | 🟢 | Line 597: risks_high carries style="display: none" with no inner <li>, matching ER line 229 (“No risk reaches High”). |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | All eight rows come from the ER Monitoring Protocol & Defining Success biomarker table (ER lines 441-450). |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All eight ER biomarkers present, none omitted: seated blood pressure, standing blood pressure, resting heart rate, heart rate variability, fasting glucose, glycated haemoglobin, insulin-like growth factor 1, prolactin. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Lines 747-750 condense ER line 439 into the three cadences: blood pressure at two weeks and three months, sleep measures at four weeks, blood markers every six to twelve months. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | All five items come from the ER qualitative-marker list at lines 454-458. |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All five ER qualitative markers present and carried verbatim (lines 760, 765, 770, 775, 780). |
Issues 19/09/2026 03:30
Pass rate 100.00%. No issues found.
Issues 19/09/2026 03:19
- 9.5 — Interaction example term substituted: Line 585 renders the ER’s named example “Cognitive behavioural therapy for insomnia” (ER line 315) as “(insomnia therapy)”, a term absent from the ER that denotes a broader class than the specific protocol the ER names.
Fixes 19/09/2026 03:19
- 9.5 — Interaction example term restored: Replaced the invented parenthetical “(insomnia therapy)” in the Key Interactions gate with “(cognitive behavioural therapy)”, the ER’s own named example from its
Key Interactions & Contraindicationsbullet.
Issues 19/09/2026 03:14
- 4.5 — Sheet overruns one A4 page: The combined stack — six contraindications, ten Key Interactions, an eight-row monitoring table, a six-item Low benefits line, a five-item Low risks line and five qualitative items — exceeds the single-page budget at the template’s 9pt/9.5pt card sizes; the Key Interactions gate (lines 576–585) is the largest condensable block.
Fixes 19/09/2026 03:14
-
4.5 — Key Interactions parentheticals trimmed: Reduced the example-drug lists on six of the ten interaction items to their shortest representative form (e.g. “(lisinopril, losartan, amlodipine)” to “(lisinopril, amlodipine)”, “(valerian, kava, melatonin, L-Theanine)” to “(valerian, melatonin)”), bringing the gate from sixteen rendered lines to twelve while keeping at least one named example on every item.
-
4.5 — Contraindication items condensed: Shortened two over-wrapping gate items to single lines (“seated systolic pressure below 100 mmHg” to “seated systolic below 100 mmHg”; “outside a supervised clinical trial” to “outside a clinical trial”), preserving the 100 mmHg threshold and the trial-supervision qualifier.
-
4.5 — Monitoring table cells condensed: Trimmed six “Why” cells and three “Target” cells to single clauses (e.g. “Detects sustained growth-signalling elevation from repeated gram-level dosing” to “Sustained growth signalling from gram-level dosing”; “Below 15 ng/mL in men, below 20 ng/mL in non-pregnant women” to “Under 15 ng/mL (men), 20 ng/mL (non-pregnant women)”), cutting the eight-row table from sixteen rendered lines to ten with all numeric targets intact.
-
4.5 — Monitoring cadence shortened: Condensed the cadence sentence from 188 to 151 characters (“at two weeks and again at three months” to “at two weeks and three months”; “or sooner if gram-level dosing is used” to “or sooner at gram-level dosing”).
Issues 19/09/2026 03:04
- 4.2 / 4.3 — Key Interaction labels paraphrased: Four [caution_items] shorten the ER’s bold labels instead of reproducing them verbatim — “Antihypertensive medication” → “Antihypertensives” (QRS line 576), “Antiepileptic drugs” → “Antiepileptics” (line 579), “Over-the-counter sleep aids and antihistamines” → “Sleep aids and antihistamines” (line 582), and “Sedating botanical supplements” → “Sedating botanicals” (line 584).
Fixes 19/09/2026 03:04
- 4.2 / 4.3 — Key Interaction labels restored verbatim: Reinstated the ER’s bold labels in [caution_items] — “Antihypertensives” to “Antihypertensive medication”, “Antiepileptics” to “Antiepileptic drugs”, “Sleep aids and antihistamines” to “Over-the-counter sleep aids and antihistamines”, and “Sedating botanicals” to “Sedating botanical supplements”. The parenthetical example drug lists were left unchanged.
Issues 19/09/2026 03:02
- 4.5 / 9.5 — Sheet overflows one A4 page: The Key Interactions gate (lines 575–603) carries ten items with untrimmed ER parenthetical lists — six to seven named examples each for the blood-pressure-lowering supplements, sedating botanicals and non-pharmacological interventions — wrapping to roughly 21 rendered lines; together with the 8-row Monitoring table and the 5-item Qualitative list the sheet renders well beyond the single A4 print budget.
Fixes 19/09/2026 03:02
- 4.5 / 9.5 — Key Interactions trimmed to page budget: Shortened the ten [caution_items] parenthetical example lists to two to four representative agents each (e.g. blood-pressure-lowering supplements from “beetroot or dietary nitrate, hibiscus, aged garlic extract, potassium, magnesium, fish oil” to “nitrate, hibiscus, magnesium”), and condensed the item stems (“Antihypertensive medication” to “Antihypertensives”, “Over-the-counter sleep aids and antihistamines” to “Sleep aids and antihistamines”), cutting the gate from roughly 21 rendered lines to roughly 13 while retaining every interaction category.